June 10, 2019

WindCorp acted as the financial advisor to Nazca Capital on the acquisition of an 85% stake of the biopharmaceutical company Diater to the Pharma group Ferrer

With this operation, valued at 45 million euros, Nazca Capital joins Diater’s shareholding with the aim of boosting its growth and expansion in new markets around the world.


Nazca Capital is a Spanish Private Equity firm which invests in non-listed Spanish medium sized companies (sales between €30 and €200 million), through acquisition of shares and capital increases. This is the fifth operation of the Nazca IV Fund, created in 2017 with €275 million under management, to invest in ‘SMEs’ by the Private Equity firm that directs Carlos Carbó and Álvaro Mariátegui.

Diater is a biopharmaceutical Spanish company pioneer in the treatment of allergy with immunotherapy. The company was founded in 1999 and in these 20 years of experience has specialized in the manufacture of diagnostic products and treatment of immunotherapy for allergic diseases. Diater reached a sales volume of 17 million euros and an EBITDA of 5 million at the end of 2018. By the end of 2019, the company expects to reach sales of 20 million euros.

This new stage represents an opportunity for Diater to “boost its growth” through new investments to expand its capacity, strengthen its production area and boost R&D innovation and the development of new diagnostic and treatment products.


In this operation WindCorp Translink has advised Nazca Capital, together with PWC and Herbert Smith, while the consulting firm Deloitte has advised the sellers.

WindCorp Translink is a Corporate Finance firm that provides financial services to both national and international companies either listed or in the midmarket segment.

©2019 WindCorp Translink. All rights reserved.

Head Office

Avda. Diagonal 453 bis, 1º
08036 Barcelona
Phone: (+34) 93 419 49 00
Fax: (+34) 93 439 91 24
Email: windcorp@windcorp.net